Thursday, 15 November 2018

Agilent Technologies concludes acquisition of ProZyme

02 August 2018 | News

This acquisition expands Agilent’s portfolio of biopharma consumables.

Agilent Technologies has completed the acquisition of ProZyme, Inc., a leading provider of glycan reagents, kits and standards. This acquisition expands Agilent’s portfolio of biopharma consumables.


Founded in 1990, Hayward-Calif. based ProZyme is an industry leading developer and manufacturer of glycan reagents, kits and standards, which are required for efficient sample prep in the analysis of free glycans.


Glycobiology is one of the fastest-growing segments in biopharma, as glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research.


The acquisition of ProZyme follows the recent acquisition of Ultra Scientific, a leading provider of chemical standards and certified reference materials.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Click Here!

Survey Box

Will the health insurance sector receive benefits from Ayushman Bharat?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls